| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02460679 | Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | 19 | — | — | Jan 14, 2016 | Feb 23, 2018 | Oct 14, 2020 | 3 | United States |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious AEs. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.
| Arm | Type | Description |
|---|---|---|
| EPI-589 | EXPERIMENTAL | Participants will receive EPI-589 500 milligrams (mg) (2 tablets of 250 mg each) twice daily (BID) for 3 months, unless discontinued for safety or tolerability issues. |
| Name | Type | Description |
|---|---|---|
| EPI-589 | DRUG | An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm. |
Inclusion Criteria: * Diagnosis of possible, probable, laboratory supported probable, or definite ALS by E1 Escorial Criteria * Forced vital capacity (FVC) ≥ 70% of predicted * Weakness onset within 3 years * Agreement to use contraception if within reproductive years * Willingness and ability to c...